ADCs newly into human trials include Lilly's PTK7 and two bispecifics.
ApexOnco Front Page
Recent articles
7 July 2025
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
30 June 2025
Degraders of CDK2 and KRAS follow the group's attempts at inhibiting these targets.
30 June 2025
Adverse events will be closely watched when full data are reported.
26 June 2025
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
26 June 2025
The company reckons its immunotherapy could improve on Keytruda.